Pacific biosciences of california stock.
Let’s take a look at how Pacific Biosciences of California Inc’s stock performed this quarter. Earnings: $-0.28 per share, versus the consensus estimate of $-0.32 per share, according to AAII’s Stock Investor Pro, Refinitiv and I/B/E/S. Revenue: $39 million, versus $33 million in the same period one year ago.
Get the latest Pacific Biosciences of California Inc. (PACB) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.finance.yahoo.com - October 6 at 3:53 PM. Pacific Biosciences of California, Inc. (NASDAQ:PACB) Insider Sells $162,529.08 in Stock. marketbeat.com - September 29 at 8:19 PM. Bernstein Initiates Coverage of Pacific Biosciences of California (PACB) with Outperform Recommendation. msn.com - September 28 at 11:07 …April 11, 2023 at 12:00 PM · 4 min read. Pacific Biosciences of California (PACB) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in ...Track Pacific Biosciences of California Inc (PACB) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors
April 11, 2023 at 12:00 PM · 4 min read. Pacific Biosciences of California (PACB) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in ...Dec 4, 2023 · Ulysses Erickson. December 4, 2023. Company. Pacific Biosciences of California Inc (NASDAQ:PACB) has a beta value of 1.83 and has seen 0.81 million shares traded in the recent trading session. The company, currently valued at $2.37B, closed the recent trade at $8.86 per share which meant it lost -$0.02 on the day or -0.17% during that session. Pacific Biosciences of California, Inc. is a life science technology company. The Company designs, develops and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. ... Stock Pacific Biosciences of California, Inc. - Nasdaq . News Pacific Biosciences of …
Find real-time PACB - Pacific Biosciences of California Inc stock quotes, company profile, news and forecasts from CNN Business.
As of November 1, 2023, Canaccord Genuity analyst Kyle Mikson has reaffirmed a Buy rating on Pacific Biosciences (NASDAQ:PACB), although ... Best stocks to buy now; Categories. Crypto; Dow Jones today; Pre-IPO and startups; Tech stocks; Utility stocks; Best Stocks tools HOT. Stock News Sentiment;٢٥/٠١/٢٠٢٣ ... Menlo Park, California-based PacBio sold approximately 11.2 million shares in a private investment in public equity (PIPE) financing in 2021 ...Pacific Biosciences of California (PACB): Stock Market Performance, Earnings Growth, and Market Analysis. On June 30, 2023, Pacific Biosciences of California (PACB) had a mixed performance in the stock market. The stock opened at $13.77 and fluctuated between $13.59 and $14.07 throughout the day. The trading …Pacific Biosciences of California's CEO is Christian O. Henry, appointed in Sep 2020, has a tenure of 3.17 years. total yearly compensation is $6.62M, comprised of 10.1% salary and 89.9% bonuses, including company stock and options. directly owns 0.088% of the company’s shares, worth $2.03M.
Asia Pacific; CORPORATE INQUIRIES ... California 6965 Lusk Boulevard San Diego, CA 92121 USA ... United Kingdom Rolling Stock Yard 188 York Way London, N7 9AS UK ...
Pacific Biosciences. Pacific Biosciences of California, Inc. (aka PacBio) is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. [2] [3] [failed verification] PacBio has two principal sequencing platforms: single-molecule real-time ...
Pacific Biosciences of California, Inc. has a twelve month low of $5.74 and a twelve month high of $14.55. The stock has a market cap of $2.37 billion, a P/E ratio of -6.99 and a beta of 1.78. The ...Nov 13, 2023 · Pacific Biosciences of California Inc does not have a meaningful P/E due to negative earnings over the last 12 trailing months. Pacific Biosciences of California Inc’s trailing 12-month revenue is $169.5 million with a -182.3% profit margin. Year-over-year quarterly sales growth most recently was 72.4%. Pacific Biosciences of California last issued its quarterly earnings results on October 30th, 2023. The biotechnology company reported ($0.27) earnings per share for …SAN DIEGO & MENLO PARK, Calif.--(BUSINESS WIRE)-- Illumina, Inc. (NASDAQ:ILMN) and Pacific Biosciences of California, Inc. (NASDAQ:PACB) today announced that they have mutually agreed to terminate their merger agreement, previously announced on November 1, 2018, under which Illumina would acquire Pacific …This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled ...Nov 24, 2023 · Stock analysis for Pacific Biosciences of California Inc (PACB:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
One such stock that merits attention is Pacific Biosciences of California Inc ( NASDAQ:PACB ). The stock, which is currently priced at 10.06, recorded a loss of 3.5% in a day and a 3-month ...Natural resources in California include waterways such as the San Joaquin Delta, the Pacific Ocean coastline, natural parks, plants and wildlife, and numerous habitats and ecosystems. Natural resources in California provide many economic an...Nov 15, 2023 · Pacific Biosciences of California Inc is up 8.17% from its previous closing price of $7.22. During the last market session, Pacific Biosciences of California Inc’s stock traded between $7.00 and $7.43. Currently, there are 255.00 million shares of Pacific Biosciences of California Inc stock available for purchase. The notes will have a conversion price of $43.50 per share of the company's common stock, representing a 10% premium over Pacific Biosciences' share price as of the end of yesterday's trading session.Pacific Biosciences of California stock monthly and weekly forecasts. Skip to content. FORECST.COM 2023 – 2026 Stock Market Forecast PACB stock forecast for 2023 – 2027. Last updated: October 11, 2023. Are you interested in Pacific Biosciences of California, Inc. stocks prediction?Interactive Chart for Pacific Biosciences of California, Inc. (PACB), analyze all the data with a huge range of indicators.
Pacific Biosciences of California, Inc. 1305 O’Brien Drive, Menlo Park, CA 94025 [email protected] Email Alerts The Investor Relations website contains information …Complete Pacific Biosciences of California Inc. stock information by Barron's. View real-time PACB stock price and news, along with industry-best analysis.
Find the latest Pacific Biosciences of California, Inc. (PACB) stock quote, history, news and other vital information to help you with your stock trading and investing.Nov 27, 2023 · The average twelve-month price prediction for Pacific Biosciences of California is $11.80 with a high price target of $17.00 and a low price target of $8.00. Learn more on PACB's analyst rating history. Do Wall Street analysts like Pacific Biosciences of California more than its competitors? Pacific Biosciences of California Inc. PACB (U.S.: Nasdaq) Pacific Biosciences of California Inc. View All companies. REAL TIME 12:47 PM EST 11/30/23. $8.62 USD.Pacific Biosciences of California, Inc. Common Stock (PACB) 0 Add to Watchlist Add to Portfolio Quotes Summary Real-Time Key Data Bid Price and Ask Price The bid & ask …The stock of Pacific Biosciences of California (PACB 2.27%), a company developing DNA sequencing machines, is losing ground after an investor update. Preliminary fourth-quarter sales figures ...Published: SATURDAY DECEMBER 2, 2023. Pacific Biosciences of California (PACB) stock hit day 0 of a continuous streak of days with losses, with cumulative ...
Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Free Report) gapped up prior to trading on Friday .The stock had previously closed at $6.52, but opened at $6.92. Pacific Biosciences ...
Oct 31, 2023 · PacBio Announces Third Quarter 2023 Financial Results. MENLO PARK, Calif. , Oct. 30, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2023 . Third quarter results Revenue of $55.7 million , a 72% increase compared with $32.3 million in the prior-year period. October 30, 2023.
Complete Pacific Biosciences of California Inc. stock information by Barron's. View real-time PACB stock price and news, along with industry-best analysis. Mar 31, 2023 · Pacific Biosciences of California Inc’s price is currently up 27.53% so far this month. During the month of March, Pacific Biosciences of California Inc’s stock price has reached a high of $11.79 and a low of $8.01. Over the last year, Pacific Biosciences of California Inc has hit prices as high as $14.20 and as low as $3.85. Pacific Biosciences of California Inc’s ( PACB) price is currently down 20.92% so far this month. During the month of February, Pacific Biosciences of California Inc’s stock price has reached a high of $12.35 and a low of $8.71. Over the last year, Pacific Biosciences of California Inc has hit prices as high as $14.20 and as low as $3.85.Pacific Biosciences of California, Inc. 1305 O’Brien Drive, Menlo Park, CA 94025 [email protected] Email Alerts The Investor Relations website contains information …Get the latest Pacific Biosciences of California, Inc. (PACB) stock news and headlines to help you in your trading and investing decisions. ... Pacific Biosciences of California, Inc. (NASDAQ:PACB ...Pacific Biosciences of California, Inc. ("PacBio") (NASDAQ: PACB) today announced that it has entered into a privately negotiated exchange agreement with a holder of PacBio's outstanding 1.50% ...Pacific Biosciences of California, Inc. Common Stock (PACB) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Oct. 30, 2023, 04:07 PM. (RTTNews) - Pacific Biosciences of California, Inc. (PACB) released Loss for third quarter that decreased from the same period last year and beat the Street estimates. The ...The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA. Pacific Biosciences of California Inc. 1305 O'Brien Drive. Menlo ...
Christian O. Henry. Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template ...٢٥/٠١/٢٠٢٣ ... Menlo Park, California-based PacBio sold approximately 11.2 million shares in a private investment in public equity (PIPE) financing in 2021 ...Pacific Biosciences of California Stock Up 2.3 %. Shares of NASDAQ:PACB opened at $8.55 on Friday. The company has a debt-to-equity ratio of 1.17, a current ratio of 4.80 and a quick ratio of 4.43.Instagram:https://instagram. percent.com reviewsamd vs nvidia stockbest ppo health insurance in floridaprestigious investment banks ١٢/١٠/٢٠٢٣ ... Shares of Pacific Biosciences of California (PACB) - Get Free Report, a life science technology company focused on solving genetic problems, ... cgdv etfcooper std ٣٠/٠٨/٢٠٢٣ ... Pacific Biosciences of California (PacBio; PACB) shares have doubled year-over-year, zooming 101% despite a 26% decline earlier this month. trading options courses A steep rise in short interest was recorded in Pacific Biosciences of California Inc stocks on Oct 30, 2023, growing by 2.05 million shares to a total of 35.12 million shares. Yahoo Finance data shows the prior-month short interest on Sep 28, 2023 was 33.07 million shares. There was a rise of 5.84%, which implies that there is a …Pacific Biosciences of California (NASDAQ:PACB) and Olink Holding AB (publ) are both mid-cap medical companies, but which is the superior business?We will compare the two businesses based on the strength of their profitability, institutional ownership, community ranking, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.